Kai Liang

Title: Innovations of Kai Liang in Tumor Detection

Introduction

Kai Liang is an innovative inventor based in Beijing, China. He has made significant contributions to the field of cancer detection through his groundbreaking patent. His work focuses on the development of a rapid and ultrasensitive assay for quantifying tumor-derived extracellular vesicles (EVs) in plasma microsamples.

Latest Patents

Kai Liang holds a patent titled "Nanoplasmonic quantification of tumor-derived extracellular vesicles in plasma microsamples for detection and treatment monitoring." This innovative assay utilizes a nanoplasmon-enhanced scattering (nPES) technique that allows for the direct quantification of tumor-derived EVs from as little as 1 μL of plasma. The method employs the binding of gold nanospheres and nanorods with specificities to EVs and tumor-derived EVs, producing a local plasmon effect that enhances the sensitivity and specificity of tumor-derived EV detection. This non-invasive approach is particularly valuable for assessing pancreatic cancer stages and treatment responses, and it can be adapted for diagnosing and monitoring other conditions with disease-specific EV proteins. Kai Liang has 1 patent to his name.

Career Highlights

Throughout his career, Kai Liang has worked with notable institutions, including The Methodist Hospital and Houston Methodist. His work has been instrumental in advancing the field of cancer diagnostics, particularly through the application of nanotechnology in medical assays.

Collaborations

Kai Liang has collaborated with esteemed colleagues such as Ye Hu and Jia Fan, contributing to the development of innovative solutions in the medical field.

Conclusion

Kai Liang's contributions to cancer detection through his patented technology exemplify the potential of innovative approaches in medicine. His work not only enhances the sensitivity of tumor detection but also paves the way for non-invasive diagnostic methods.